1 managed care digest series ®, © 2013 sanofi-aventis u.s. llc, a sanofi company data source: ims...
Post on 27-Dec-2015
215 Views
Preview:
TRANSCRIPT
1 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Featuring Demographic, Charge, Pharmacotherapy and Hospital Utilization Data for Diabetes Patients
South Carolina Market BriefDiabetes
2 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Sample Managed Care Digest Series® Data Sets
Patient Claims Data (Diabetes, AFib/AFlutter, Oncology):National, Regional, State, MSA Data– 2012 Data
Hospital Profile and Discharge Data (59 Disease States): National, Regional, State, MSA, System and Individual Hospital Data– 2011 Data
Health Plan Data (HMOs):National, Regional, State and MSA Data– 2012 Data
Retail Pharmacy Data (60+ Drug Classes/Subclasses):National, Regional and State Data– Midyear 2012 Data (updated to midyear 2013 in September)
3 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Tracking Patients Across the Continuum of Care
4 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Diabetes patient claims data are generated by IMS Health for the Managed Care Digest Series® using health care professional and institutional insurance claims. In 2012, data represented more than 7.1 million unique patients nationally with a diagnosis of Type 2 diabetes. Data from physicians of all specialties and from all hospital types are included.
IMS Health also gathers data on prescription activity from the National Council for Prescription Drug Programs (NCPDP). These data account for some 2 billion prescription claims annually, or more than 50% of the prescription universe. These prescription data represent the sampling of prescription activity from a variety of sources, including retail chains, mass merchandisers and pharmacy benefit managers. Cash, mail order, Medicaid and third-party transactions are tracked.
Diabetes Patient Claims Data
5 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Percentage of Type 1 and Type 2 Diabetes Patients, by Payer, 2012
Medicare Medicaid Commercial Insurance1
Market Type 1 Type 2 Type 1 Type 2 Type 1 Type 2
Charleston 29.6% 44.5% 11.8% 7.8% 58.6% 45.3%
Columbia 21.9% 43.4% 16.5% 6.8% 58.5% 48.4%
Florence 29.7% 49.2% 19.0% 13.9% 51.3% 35.9%
Greenville 22.5% 46.7% 15.8% 8.0% 61.7% 44.3%
Myrtle Beach — 52.6% — 8.3% — 37.5%
Sumter — 49.2% — 10.7% — 36.9%
South Carolina 27.5% 47.3% 14.9% 9.0% 55.8% 42.3%
NATION 19.0% 39.1% 10.9% 9.8% 69.2% 50.5%
1 Includes HMOs, PPOs, point-of-service plans and exclusive provider organizations.NOTE: Throughout this presentation, the Charleston market includes North Charleston, and the Greenville market includes Spartanburg and
Anderson. Some demographic data for Type 1 diabetes patients were unavailable for Myrtle Beach and Sumter.
6 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Percentage of Type 1 Diabetes Patients, by A1c Level Range1
≤7.0% 7.1–7.9% 8.0–9.0% >9.0%
Market 2010 2011 2012 2010 2011 2012 2010 2011 2012 2010 2011 2012
South Carolina 30.0% 29.0% 32.9% 24.6% 24.7% 21.7% 16.7% 18.4% 18.8% 28.8% 27.8% 26.7%
NATION 28.2% 27.7% 28.1% 26.5% 26.1% 25.5% 22.4% 22.0% 22.0% 22.9% 24.2% 24.4%
1 The A1c test measures how much glucose has been in the blood during the past 2–3 months.Note: A1c level data data were unavailable for Type 1 diabetes patients in Charleston, Columbia, Florence, Greenville, Myrtle Beach and Sumter. Some A1c level data were unavailable for Greenville.
7 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
≤7.0% 7.1–7.9% 8.0–9.0% >9.0%
Market 2010 2011 2012 2010 2011 2012 2010 2011 2012 2010 2011 2012
Charleston 46.5% 48.0% 44.8% 22.5% 20.5% 21.8% 13.7% 13.0% 13.6% 17.3% 18.6% 19.9%
Columbia 47.2% 49.2% 45.8% 20.9% 19.9% 21.0% 14.5% 12.6% 13.4% 17.4% 18.3% 19.9%
Florence 48.5% 47.3% 45.9% 21.9% 19.5% 18.9% 13.3% 13.3% 13.9% 16.3% 19.8% 21.3%
Greenville 50.2% 54.1% 51.3% 22.1% 19.5% 19.2% 13.2% 12.3% 13.6% 14.5% 14.1% 15.9%
Myrtle Beach 50.3% 51.5% 48.8% 23.3% 21.9% 21.3% 13.8% 12.0% 14.2% 12.6% 14.6% 15.7%
Sumter 50.2% 50.7% 47.2% 23.6% 19.7% 19.4% 12.4% 13.4% 12.6% 13.8% 16.1% 20.9%
South Carolina 48.5% 50.7% 47.4% 22.0% 20.1% 20.4% 13.7% 12.4% 13.7% 15.8% 16.8% 18.6%
NATION 50.2% 51.1% 50.6% 22.0% 20.7% 20.6% 13.3% 12.6% 12.9% 14.6% 15.6% 15.9%
Percentage of Type 2 Diabetes Patients, by A1c Level Range1
1 The A1c test measures how much glucose has been in the blood during the past 2–3 months.
8 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Percentage of Type 1 Diabetes Patients, by Actual Complication, 20121
MarketCardiovascular
DiseaseHypoglycemia Nephropathy Neuropathy Retinopathy
Charleston 45.3% 9.4% 25.5% 28.3% 41.5%
Columbia 58.7% — 22.8% 30.4% 35.9%
Florence 44.1% — 49.2% 20.3% 22.0%
Greenville 36.0% 13.7% 26.6% 38.1% 27.3%
South Carolina 46.0% 13.5% 31.3% 32.6% 28.1%
NATION 35.9% 16.5% 27.3% 28.7% 32.8%
1 A complication is defined as a patient condition caused by the Type 1 diabetes of the patient. These conditions are a direct result of having Type 1 diabetes. Complications of Type 1 diabetes include, but are not limited to, cardiovascular disease, hypoglycemia, nephropathy, neuropathy and retinopathy.
Note: Some complications data were unavailable for Columbia and Florence.
9 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Percentage of Type 2 Patients, by Actual Complication, 20121
MarketCardiovascular
DiseaseHypoglycemia Nephropathy Neuropathy Retinopathy
Charleston 52.6% 9.0% 27.7% 32.5% 29.7%
Columbia 63.9% 4.8% 21.2% 30.0% 19.8%
Florence 67.9% 6.3% 33.8% 30.5% 11.3%
Greenville 61.4% 7.7% 29.7% 35.5% 12.5%
Myrtle Beach 66.6% 8.9% 23.2% 37.3% 15.9%
Sumter 57.8% 9.5% 36.6% 42.2% 20.5%
South Carolina 61.7% 7.4% 28.0% 33.6% 16.3%
NATION 58.1% 7.3% 29.6% 31.3% 18.5%
1 A complication is defined as a patient condition caused by the Type 2 diabetes of the patient. These conditions are a direct result of having Type 2 diabetes. Complications of Type 2 diabetes include, but are not limited to, cardiovascular disease, hypoglycemia, nephropathy, neuropathy and retinopathy.
10 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Percentage of Type 2 Diabetes Patients, Using Various Insulin Therapies
Long-Acting Insulin
Rapid-Acting Insulin
Short-ActingInsulin
Market 2010 2011 2012 2010 2011 2012 2010 2011 2012
Charleston 21.3% 21.8% 22.0% 13.9% 14.4% 14.0% 15.6% 15.8% 15.0%
Columbia 20.1% 21.6% 23.1% 14.2% 14.9% 16.5% 15.3% 16.1% 17.3%
Florence 26.0% 27.8% 27.2% 17.6% 18.4% 18.2% 18.6% 19.1% 18.7%
Greenville 21.6% 22.3% 23.0% 13.4% 13.7% 13.7% 14.8% 14.9% 14.6%
Myrtle Beach 20.9% 21.9% 22.8% 12.8% 13.2% 14.0% 14.5% 14.7% 15.4%
Sumter 25.3% 24.7% 24.6% 18.8% 19.4% 19.2% 19.7% 20.3% 19.7%
South Carolina 21.6% 22.5% 23.2% 14.1% 14.5% 14.8% 15.5% 15.7% 15.8%
NATION 23.0% 23.6% 24.9% 14.9% 15.3% 16.0% 17.0% 17.1% 17.6%
11 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Percentage of Type 2 Diabetes Patients,Using Various Therapies
Intermediate-Acting Insulin
Mixed Insulin
2+ Non-Insulin Products
Market 2010 2011 2012 2010 2011 2012 2010 2011 2012
Charleston 2.7% 2.5% 2.1% 7.9% 7.1% 6.5% 24.8% 25.1% 22.6%
Columbia 2.1% 2.1% 1.6% 8.1% 7.5% 6.9% 26.3% 26.4% 23.9%
Florence 2.2% 1.8% 1.5% 9.9% 9.3% 9.2% 23.5% 23.0% 22.5%
Greenville 2.8% 2.3% 1.8% 7.5% 6.5% 5.8% 26.5% 26.4% 24.1%
Myrtle Beach 2.5% 2.1% 2.2% 6.4% 6.0% 6.0% 7.5% 7.4% 6.2%
Sumter 2.3% 1.9% 1.6% 8.3% 6.9% 6.9% 7.1% 7.8% 6.2%
South Carolina 2.5% 2.2% 1.8% 7.7% 6.9% 6.4% 26.3% 26.3% 24.1%
NATION 2.7% 2.3% 2.0% 6.7% 6.0% 5.7% 29.3% 28.4% 26.7%
12 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Any Insulin Products
Long-Acting Insulin
Rapid-Acting Insulin
Vials Pens Vials Pens
Market % $ % $ % $ % $ % $
Charleston 32.3% $1,895 8.4% $1,046 15.2% $1,274 6.9% $1,460 8.4% $1,156
Columbia 33.0% $2,157 8.2% $1,220 16.6% $1,366 7.0% $1,476 10.7% $1,188
Florence 38.2% $2,251 11.3% $1,231 18.1% $1,445 7.7% $1,210 12.1% $1,476
Greenville 31.9% $2,100 10.0% $1,340 14.5% $1,414 6.7% $1,548 8.0% $1,301
Myrtle Beach 32.6% $2,060 9.1% $1,375 15.1% $1,454 6.8% $1,264 8.0% $1,287
Sumter 34.5% $2,093 8.9% $1,093 17.1% $1,233 7.5% $1,540 13.0% $1,190
South Carolina 32.8% $2,079 9.4% $1,252 15.3% $1,373 7.0% $1,455 9.0% $1,261
NATION 33.9% $2,079 11.3% $1,256 15.3% $1,334 8.0% $1,413 9.2% $1,303
Percentage of and Average Annual Payments1 for Type 2 Diabetes Patients Using Various Insulin Therapies, 2012
1 Figures reflect the per-patient yearly payments for Type 2 diabetes patients receiving a particular type of therapy. These are the actual amounts paid by the insurer and patient for such prescriptions. Costs mainly include copayments, but can also include tax, deductibles and cost differentials where applicable.
13 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Percentage of and Average Annual Payments1 for Type 2 Diabetes Patients Using Various Insulin Therapies, 2012
Short-Acting Insulin
MixedInsulin
Intermediate-ActingInsulin
Vials Pens Vials Pens Vials Pens
Market % $ % $ % $ % $ % $ % $
Charleston 8.1% $1,417 8.4% $1,156 3.8% $1,246 3.1% $1,896 1.7% $607 0.4% $936
Columbia 7.8% $1,433 10.7% $1,188 3.8% $1,406 3.7% $2,110 1.4% $721 0.3% $1,366
Florence 8.6% $1,230 12.1% $1,476 5.7% $1,275 4.2% $2,253 1.5% $684 — —
Greenville 7.8% $1,455 8.0% $1,301 3.6% $1,368 2.5% $1,879 1.6% $972 0.3% $1,021
Myrtle Beach 8.4% $1,165 8.0% $1,287 3.7% $1,354 2.5% $2,191 1.9% $863 0.3% $1,351
Sumter 8.1% $1,558 13.0% $1,190 4.5% $1,333 3.1% $1,982 1.5% $834 — —
South Carolina 8.1% $1,394 9.0% $1,261 3.9% $1,344 2.9% $1,995 1.6% $816 0.3% $1,027
NATION 9.8% $1,333 9.2% $1,303 3.5% $1,345 2.6% $1,956 1.8% $782 0.3% $1,164
1 Figures reflect the per-patient yearly payments for Type 2 diabetes patients receiving a particular type of therapy. These are the actual amounts paid by the insurer and patient for such prescriptions. Costs mainly include copayments, but can also include tax, deductibles and cost differentials where applicable.
Note: Some pharmacotherapy data were unavailable for the selected markets.
14 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Any Non-Insulin Antidiabetic
Product
Insulin Sensitizing Agents (TZDs)
GLP-1 Receptor Agonists
DPP-4Inhibitors
Market % $ % $ % $ % $
Charleston 85.0% $760 5.6% $1,530 7.0% $1,981 11.5% $1,418
Columbia 82.8% $747 6.4% $1,535 5.9% $1,891 12.0% $1,452
Florence 81.6% $735 9.0% $1,511 4.3% $1,906 11.9% $1,540
Greenville 85.7% $631 7.0% $1,656 3.6% $1,893 10.3% $1,495
Myrtle Beach 84.6% $752 8.1% $1,646 5.6% $2,130 11.3% $1,465
Sumter 83.5% $882 5.0% $1,470 7.5% $2,012 15.0% $1,604
South Carolina 84.6% $704 6.8% $1,604 5.0% $1,936 11.4% $1,473
NATION 84.6% $745 7.1% $1,650 4.9% $1,964 12.8% $1,525
Percentage of and Average Annual Payments1 for Type 2 Diabetes Patients Using Various Non-Insulin Antidiabetic Therapies, 2012
1 Figures reflect the per-patient yearly payments for Type 2 diabetes patients receiving a particular type of therapy. These are the actual amounts paid by the insurer and patient for such prescriptions. Costs mainly include copayments, but can also include tax, deductibles and cost differentials where applicable.
15 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
1 Figures reflect the per-patient yearly payments for Type 2 diabetes patients receiving a particular type of therapy. These are the actual amounts paid by the insurer and patient for such prescriptions. Costs mainly include copayments, but can also include tax, deductibles and cost differentials where applicable.
Average Annual Payments per Type 2 Diabetes Patient,by Type of Therapy, 20121
16 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Endocrinology Primary Care1 Internal Medicine
MarketLong-Acting Insulin
Rapid-Acting Insulin
Short-Acting Insulin
Inter-mediate-Acting Insulin
Long-Acting Insulin
Rapid-Acting Insulin
Short-Acting Insulin
Inter-mediate-Acting Insulin
Long-Acting Insulin
Rapid-Acting Insulin
Short-Acting Insulin
Inter-mediate-Acting Insulin
Charleston 34.2% 41.4% 43.3% 8.0% 17.9% 8.1% 8.8% 5.8% 20.9% 12.0% 12.8% 6.1%
Columbia 43.7% 50.0% 51.2% 4.4% 19.3% 11.6% 12.3% 7.7% 21.9% 13.1% 14.0% 6.1%
Florence 35.9% 49.2% 50.8% 11.6% 23.5% 12.8% 13.3% 8.9% 29.0% 18.7% 19.8% 6.1%
Greenville 44.8% 50.4% 53.0% 4.3% 20.3% 10.0% 10.7% 4.8% 21.9% 11.9% 12.8% 6.9%
Myrtle Beach 29.1% 32.1% 32.9% 4.0% 18.8% 9.4% 10.6% 6.3% 21.7% 11.4% 10.6% 5.9%
Sumter 42.9% 47.2% 47.2% — 19.3% 13.4% 13.9% 5.0% 20.0% 8.8% 15.1% 8.8%
South Carolina 38.7% 43.8% 45.7% 5.4% 19.5% 10.1% 10.9% 6.0% 22.2% 12.7% 13.6% 6.6%
NATION 37.0% 36.0% 38.1% 7.1% 21.0% 10.7% 12.0% 4.8% 22.0% 12.4% 13.9% 5.5%
Percentage of Type 2 Diabetes Patients Using Various Insulin Therapies, by Prescribing Specialist, 2012
1 “Primary care” consists of both general and family practitioners.
17 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Persistency: Various Insulin Products, South Carolina, 2012
18 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Persistency: Various Non-Insulin Antidiabetic Products, South Carolina, 2012
19 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Persistency: Various Insulin Therapies, Charleston, 2012
20 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Persistency: Various Non-Insulin Antidiabetic Therapies, Charleston, 2012
21 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Persistency: Various Insulin Therapies, Greenville, 2012
22 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Persistency: Various Non-Insulin Antidiabetic Therapies, Greenville, 2012
23 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Readmission Rates for Patients Diagnosed with Type 2 Diabetes, by Type of Therapy, 2010–20121
24 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Professional Charges per Year for Type 2 Diabetes Patients, 20121
MarketAmbulatory
SurgeryEmergency
RoomHospital Inpatient
Hospital Outpatient
Office/Clinic
Charleston $3,321 $730 $3,747 $1,269 $2,154
Columbia $2,539 $1,228 $3,088 $1,312 $2,039
Florence $2,421 $722 $4,080 $1,240 $2,010
Greenville $2,208 $652 $2,664 $973 $2,172
Myrtle Beach $3,544 $557 $2,629 $1,093 $2,019
Sumter $3,462 $884 $3,152 $1,995 $3,898
South Carolina $2,713 $749 $2,987 $1,182 $2,068
NATION $2,475 $946 $2,769 $1,096 $1,846
1 Professional charges are those generated by the providers delivering care to Type 2 diabetes patients in various settings.
25 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Inpatient Outpatient
Market
Charleston $17,019 $3,777
South Carolina $19,518 $3,366
NATION $33,161 $6,750
Facility Charges per Year for Type 1 Diabetes Patients, 20121
1 Figures reflect the charges generated for Type 2 diabetes patients by the facilities that delivered care. Facility charge data include charges for all services rendered, including prevention and charges associated with the treatment of other diseases. The data also reflect the average amountscharged in Type 2 diabetes patient claims, not the amount the claims paid.
Note: Facility charges data were unavailable for Type 1 diabetes patients in Columbia, Florence, Greenville, Myrtle Beach and Sumter.
26 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Inpatient Outpatient
Market 2011 2012 2011 2012
Charleston $40,935 $46,177 $8,560 $8,199
Columbia $43,724 $48,111 $8,499 $7,932
Florence $47,617 $49,623 $8,121 $11,791
Greenville $43,347 $48,325 $11,417 $9,514
Myrtle Beach $40,591 $40,881 $7,995 $8,077
Sumter $40,887 $36,450 $7,632 $9,106
South Carolina $40,178 $44,463 $8,218 $8,109
NATION $49,150 $52,156 $10,061 $10,647
Facility Charges per Year for Type 2 Diabetes Patients1
1 Figures reflect the charges generated for Type 2 diabetes patients by the facilities that delivered care. Facility charge data include charges for all services rendered, including prevention and charges associated with the treatment of other diseases. The data also reflect the average amounts charged in Type 2 diabetes patient claims, not the amount the claims paid.
27 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Hospital Discharges
28 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Inpatient Outpatient
Market Average Total Average Total
Charleston 1,717.1 15,454 7,466.9 59,735
Columbia 2,881.8 14,409 11,681.2 58,406
Florence 2,798.0 8,394 7,729.7 23,189
Greenville 1,559.4 21,831 8,244.2 98,930
Myrtle Beach 1,257.8 5,031 7,763.7 23,291
South Carolina 1,425.6 95,518 6,064.2 382,043
NATION 1,282.8 6,382,133 5,251.4 25,574,123
Total and Average Number of Inpatient and Outpatient Diabetes Mellitus Cases per Hospital, 2011
Note: For slides 25–29, diabetes mellitus hospital discharge data were unavailable for Sumter.
29 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Market Medicare Medicaid Commercial Insurance1
Charleston 59.3% 9.6% 18.1%
Columbia 54.4% 12.7% 22.6%
Florence 70.0% 9.2% 15.3%
Greenville 66.7% 9.6% 16.8%
Myrtle Beach 64.3% 9.9% 16.6%
South Carolina 63.8% 10.3% 17.8%
NATION 60.1% 11.9% 19.8%
Percentage of Inpatient Diabetes Mellitus Cases, by Payer, 2011
1 Includes HMOs, PPOs, point-of-service plans and exclusive provider organizations.
30 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Market Primary Secondary
Charleston 8.0% 92.0%
Columbia 8.4% 91.6%
Florence 9.3% 90.7%
Greenville 8.2% 91.8%
Myrtle Beach 7.6% 92.4%
South Carolina 8.7% 91.3%
NATION 8.5% 91.6%
Percentage of Inpatient Diabetes Mellitus Cases, by Primary vs. Secondary Diagnosis, 2011
31 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
MarketHome/
RoutineShort Term
Hospital
Skilled Nursing Facility
Intermediate Care Facility
Other Facility1
Home Health
Against Advice
Died Other2
Charleston 71.1% 0.7% 8.5% 0.6% 0.4% 14.0% 0.2% 1.0% 3.5%
Columbia 69.2% 0.8% 10.7% 0.7% 0.4% 14.2% 0.3% 1.1% 2.7%
Florence 73.4% 1.1% 7.1% 0.7% 0.4% 11.2% 0.5% 1.3% 4.4%
Greenville 68.6% 0.9% 10.8% 1.2% 0.6% 13.9% 0.3% 1.0% 2.6%
Myrtle Beach 68.5% 1.4% 9.9% 0.8% 0.2% 14.9% 0.6% 1.6% 2.1%
South Carolina 68.3% 1.5% 10.4% 0.8% 0.4% 14.1% 0.3% 1.2% 2.9%
NATION 63.3% 2.0% 12.9% 1.0% 1.2% 15.0% 0.9% 1.2% 2.5%
Percentage of Inpatient Diabetes Mellitus Cases, by Discharge Destination, 2011
1 “Other Facility” represents patients discharged or transferred to federal health care facilities, Medicare-certified long-term hospitals or critical-access hospitals.2 “Other” represents mental health/rehabilitation, shelters, hospice (home) and hospice (medical facility).
32 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
ALOS Average Charges1
Market 2010 2011 2010 2011
Charleston 5.1 4.7 $44,250 $42,209
Columbia 6.4 6.8 $44,338 $43,340
Florence 5.0 5.5 $40,005 $53,399
Greenville — 4.8 $36,810 $36,537
Myrtle Beach 5.2 4.4 $30,416 $27,724
South Carolina 5.3 4.6 $34,089 $35,614
NATION 4.3 4.3 $34,505 $36,624
Average Length of Stay (Days) and Total Average Charges per Inpatient Diabetes Mellitus Case
1 Data reflect the average amounts charged, not the amounts paid. Charges include the treatment of other diseases besides diabetes mellitus.Note: Some average length of stay data were unavailable for Greenville.
33 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Most Common Concomitant Diagnoses for Patients With a Primary Diagnosis of Diabetes Mellitus, 2011
South Carolina Hospitals
ICD-9 CODE Description Overall
401.9 Unspecified Essential Hypertension 21.1%
272.4 Other and Unspecified Hyperlipidemia 12.4%
584.9 Unspecified Acute Renal Failure 11.0%
276.51 Dehydration 8.3%
707.15 Ulcer of Other Part of Foot 7.7%
305.1 Nondependent Tobacco Use Disorder 6.9%
357.2 Polyneuropathy in Diabetes 6.7%
403.90Hypertensive Chronic Kidney Disease, Unspecified, with Chronic Kidney Disease, Stage I through Stage IV, or Unspecified 6.5%
NOTE: Most common concomitant diagnoses data are available down to the state level only.
34 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Most Common Procedures for PatientsWith a Primary Diagnosis of Diabetes Mellitus, 2011
NOTE: Most common procedures data are available down to the state level only
South Carolina Hospitals
ICD-9 CODE Description Overall
39.95 Hemodialysis 7.5%
38.93 Venous Catheterization, Not Elsewhere Classified 7.0%
99.04 Transfusion of Packed Cells 6.5%
86.22 Excisional Debridement of Wound, Infection or Burn 3.0%
38.97 Central Venous Catheter Placement with Guidance 2.1%
88.48 Ateriography of Femoral and Other Lower Extremity Artery 1.7%
35 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
36 Managed Care Digest Series®, © 2013 sanofi-aventis U.S., A SANOFI COMPANY Data source: IMS Health © 2013
Claims Data (slides 5–26)
•Data for this presentation were generated by IMS Health for the Managed Care Digest Series® using health care professional and institutional insurance claims. Data for this presentation represent more than 7.2 million unique patients nationally in 2012 with a diagnosis of Type 1 or Type 2 diabetes. Data from physicians of all specialties and from all hospital types are included.
•IMS Health also gathers data on prescription activity from the National Council for Prescription Drug Programs (NCPDP). These data account for some 2 billion prescription claims annually, or more than 50% of the prescription universe. These prescription data represent the sampling of prescription activity from a variety of sources, including retail chains, mass merchandisers and pharmacy benefit managers. Cash, mail order, Medicaid and third-party transactions are tracked.
Hospital Procedure/Diagnosis (HPD) Discharge Data (slides 28–34):
•Demographic, utilization and charge data are derived from IMS Health’s HPD database. This database contains an extensive set of hospital inpatient discharge records, including actual diagnosis and procedure data for about 75% of all discharges nationwide (including 100% of Medicare-reimbursed discharges).
•IMS Health uses Medicare procedure counts and additional hospital-level information to estimate procedure counts for the remaining 25% of discharges—the non-Medicare hospital discharge information in non-reporting states.
•The HPD inpatient database also reports the numbers of procedures performed on patients discharged from a hospital.
•The hospital inpatient data provided are current as of calendar year 2011.
Methodology
37 Managed Care Digest Series®, © 2013 sanofi-aventis U.S. LLC, A SANOFI COMPANY Data source: IMS Health © 2013
Market Type 1 Diabetes Type 2 Diabetes
Charleston, SC 248 20,911
Columbia, SC 302 24,505
Florence, SC 170 10,980
Greenville, SC 499 42,406
South Carolina 1,690 155,833
NATION 141,620 7,139,402
Claims Data Sample Sizes
top related